Trump/Cook, Nissan weakness, more tariffs and gold - what’s moving markets
Joshua Schafer, Chief Commercial Officer and Executive Vice President of Business Development at Zevra Therapeutics, Inc. (NASDAQ:ZVRA), sold 10,500 shares of the company's common stock on February 13, 2025. The shares were sold at an average price of $7.8597 each, resulting in a total transaction value of $82,526. The transaction occurred with the stock trading near its current price of $8.07, in a company valued at approximately $430 million. Following this sale, Schafer retains ownership of 29,486 shares in the company. This transaction was conducted under a pre-established 10b5-1 trading plan, which was adopted on October 15, 2024. According to InvestingPro analysis, ZVRA shows significant stock price volatility, with analyst price targets ranging from $14 to $25. InvestingPro subscribers have access to 8 additional key insights about ZVRA, including detailed financial health metrics and comprehensive valuation analysis through the Pro Research Report, available exclusively on the platform.
In other recent news, Zevra Therapeutics, a rare disease therapeutics company, announced the successful launch of MIPLYFFA, the first FDA-approved treatment for Niemann-Pick disease type C (NPC). Early demand for the treatment has surpassed expectations and it is now being shipped to patients. The company's AmplifyAssist program aims to minimize treatment barriers and ensure consistent medication access.
On the financial front, Zevra reported a net loss for the third quarter, but emphasized a strong cash runway extending into 2027, bolstered by a successful underwritten public offering. The company reported net revenue of $3.7 million for Q3, with a net loss of $33.2 million.
Zevra faces challenges with the launch of OLPRUVA for urea cycle disorders, citing low patient awareness and reimbursement issues. However, the company plans to expand into the EU market for MIPLYFFA, with details expected in early 2024. These are among the recent developments in the company's operations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.